Prognosis of COVID-19 Patients Requiring Intensive Care Unit Care
1Department of Anesthesiology and Reanimation, Critical Care Unit, Pamukkale University, Denizli, Turkey
2Department of Internal Medicine, Pamukkale University, Denizli, Turkey
3Department of Medical Microbiology, Pamukkale University, Denizli, Turkey
DOI: 10.22514/sv.2020.16.0019 Vol.16,Issue 1,June 2020 pp.147-151
Published: 30 June 2020
Background: There is gobal concern regarding the prognosis of COVID-19 patients requiring care in the Intensive Care Unit (ICU). The aim of this study is to report the demographics, clinical features, comorbidities, imaging findings, and prognosis among critically ill patients with COVID-19 in the ICU. Methods: This retrospective study included patients with laboratory-confirmed COVID-19 infection or clinical and radiological confirmed COVID-19 infection who were admitted to adult ICUs between March 18 and April 22, 2020. Demographic data, the recent exposure history, clinical symptoms, laboratory findings and comorbidities were recorded. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were calculated. as well as mechanical ventilation parameters and blood gas results. Results: Twenty-four adult patients were admitted to the ICU with laboratory-confirmed COVID-19 (n = 15) or clinical and radiological confirmed COVID-19 (n = 9). One or more comorbidities were detected in 22/24 of the patients. All patients had abnormal radiography imaging on admission. Twenty patients had bilateral ground-glass opacification on computerized tomography (CT) scan. Almost all patients (23/24) underwent invasive mechanical ventilation therapy. Three patients underwent noninvasive mechanical ventilation. Ten patients died. The mean length of ICU stay in patients who died was 9.6 ± 9 days (2-18 days). The mean length of ICU stay of the four patients who were discharged from the ICU to the floor was 17 ± 12.9 days. The mean length of ICU stay of patients still in the ICU was (n = 10) was 13.36 ± 10.92 days. Conclusion: The vast majority of patients admitted to the ICU with the diagnosis of COVID-19 have multiple co-morbidities, require ventilator support, and experience a high mortality rate.
COVID-19, Intensive care, Viral infection
Hülya Sungurtekin,Ülkü Arslan,Cansu Özgen,İsmail Hakkı Akbudak,Mithat Kahramanoglu,Hakan Erbay,Habip Atalay,Ahmet Çalişkan,Simay Karaduman. Prognosis of COVID-19 Patients Requiring Intensive Care Unit Care. Signa Vitae. 2020. 16(1);147-151.
 Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-92.
 De Wit E, van Doremalen N, Falzarano D, Munster, VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-34.
12- january-2020-novel-coronavirus-china/en/. accessed 13 Apr 2020.
 https://tr.wikipedia.org/wiki/Turkiye%27de_2020_ koronavir%C3%BCs_pandemisi#cite_note-aa-8. accessed 18 Apr 2020.
 https://www.worldometers.info/coronavirus/, accessed 18 Apr 2020.
 Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020.
 Ranieri VM, Rubenfeld GD, Thompson BT, Thompson Tb, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526-33.
 Singer M, Deutschman CS, Seymour CW, Msc MS, Annane D, BauerM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-810.
 https://www.sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf. 18 Apr 2020.
 T. C. Ministry of Health general directorate of public health, COVID-19 (SARS-CoV-2 infection guide, Ankara. 2020. accessable on: https://covid19bilgi.saglik.gov.tr/depo/tedavi/COVID19-EriskinHastaTedavisi.
 World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. 2020. accessable on: https://www.who/int/emergencies/diseases/novel–coronavirus-2019/technical-guidance/laboratory–guidance.
 Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020.
 Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-481.
 Huang C, Wang Y, Li X, Ren L., Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical char-acteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.
 Grasselli, G, Zangrillo, A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020.
 Bai HX, Hsieh B, Xiong Z, Halsey, K, Choi, JW, Tran, TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020.
 Ai T, Yang Z, Hou H. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020;26:200642.
 Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020.
 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020.
 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the NewYork City Area. JAMA. 2020.
Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.
Editorial review: 1 - 2 days
Peer review: 1 - 2 months
Ahead of Print: within 2 months after being accepted
Notes: Your information is kept confide-ntial throughout the review process.